CRISPR-Cas9 screens in lenalidomide-treated MM cell lines. (A) sgRNA waterfallplot of MM1S cells treated with 1µM lenalidomide. (B) Significant his per cell line ranked by sgRNA z-score. (C) Clinical course (treatment schedule and paraprotein) of patient 3 and clonal evolution of mutations during sequential treatments. Arrows indicate collection of BM biopsy (auto, autologous stem cell transplantation; Bort, bortezomib; Cy, cyclophosphamide).